A Medical Device Daily

Fluidigm (South San Francisco, California) has appointed AME Bioscience (Toroed, Norway) as its exclusive distributor for the company's BioMark Systems in the Nordic region, including Norway, Sweden, Iceland, Finland and Denmark.

The BioMark System uses integrated fluidic circuits that contain a microscopic matrix of channels, valves and chambers on a silicone based chip that can perform more than 2,000 experiments at a time, providing advantages for real-time polymerase chain reaction (PCR), genotyping, cancer detection and absolute quantification, according to Fluidism.

"Fluidigm is committed to bringing the accuracy and efficiency benefits of integrated fluidic circuit technology to life science researchers in the Nordic Region," said Dominique Remy-Renou, European VP of sales, Fluidigm. "This partnership with AME Bioscience brings our technology and products along with AME's first-rate customer support to the scientists of this region."

"We are thrilled to partner with Fluidigm to bring integrated fluidic circuit technology to our customers," said Alister Ewing, director at AME. "We hope to serve as the catalyst in bringing the benefits of integrated fluidic circuit technology and Fluidigm's BioMark System to Nordic researchers."

In other agreement news: Derma Sciences (Princeton, New Jersey) reported that it has reached a three-year supply agreement for its popular Medihoney line with Amerinet (St. Louis), a healthcare group purchasing organization that serves more than 26,000 acute and non-acute healthcare providers nationwide.

The Medihoney line of dressings, containing Active Leptospermum Honey, is used for managing a variety of wounds and burns. FDA gave its initial clearance of Medihoney in July 2007, and the product was launched last fall. Two additional clearances for line extensions have been granted since then.

Derma Sciences said sales have increased rapidly, and that more than 20 clinical abstracts on the use of the product have been accepted at various professional conferences so far in 2008.